NYMCERO Trademark

Trademark Overview

On Monday, February 8, 2021, a trademark application was filed for NYMCERO with the United States Patent and Trademark Office. The USPTO has given the NYMCERO trademark a serial number of 90518513. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Monday, September 16, 2024. This trademark is owned by Purdue Pharma L.P.. The NYMCERO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Pharmaceuticals, namely, opioid antagonists; Syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Syringes filled with opioid antagonists; Injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectors filled with opioid antagonists; Injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectable pharmaceuticals, namely, opioid antagonists
nymcero

General Information

Serial Number90518513
Word MarkNYMCERO
Filing DateMonday, February 8, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateMonday, September 16, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 18, 2022

Trademark Statements

Goods and ServicesPharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Pharmaceuticals, namely, opioid antagonists; Syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Syringes filled with opioid antagonists; Injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectors filled with opioid antagonists; Injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectable pharmaceuticals, namely, opioid antagonists

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 13, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePurdue Pharma L.P.
Party Type20 - Owner at Publication
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901
Party NamePurdue Pharma L.P.
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901

Trademark Events

Event DateEvent Description
Thursday, February 11, 2021NEW APPLICATION ENTERED
Tuesday, August 31, 2021ASSIGNED TO EXAMINER
Wednesday, September 1, 2021NON-FINAL ACTION WRITTEN
Wednesday, September 1, 2021NON-FINAL ACTION E-MAILED
Thursday, May 13, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 1, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 8, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 8, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 9, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 29, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 18, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 15, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, December 10, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 18, 2022PUBLISHED FOR OPPOSITION
Tuesday, August 16, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, August 16, 2022SOU EXTENSION 1 FILED
Tuesday, August 16, 2022SOU EXTENSION 1 GRANTED
Tuesday, March 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 12, 2024SOU TEAS EXTENSION RECEIVED
Thursday, August 18, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 3, 2023SOU TEAS EXTENSION RECEIVED
Friday, March 3, 2023SOU EXTENSION 2 FILED
Friday, March 3, 2023SOU EXTENSION 2 GRANTED
Friday, September 8, 2023SOU TEAS EXTENSION RECEIVED
Friday, September 8, 2023SOU EXTENSION 3 FILED
Friday, September 8, 2023SOU EXTENSION 3 GRANTED
Tuesday, September 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 12, 2024SOU EXTENSION 4 GRANTED
Tuesday, March 12, 2024SOU EXTENSION 4 FILED
Monday, September 16, 2024SOU TEAS EXTENSION RECEIVED
Monday, September 16, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 16, 2024SOU EXTENSION 5 GRANTED
Monday, September 16, 2024SOU EXTENSION 5 FILED
Wednesday, March 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

nymcero opioid pharmaceuticals antagonists filled disorders treatment reversal overdose injectable injectors